COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
4.010
+0.180 (4.70%)
At close: Aug 30, 2024, 4:00 PM
3.950
-0.060 (-1.50%)
After-hours: Aug 30, 2024, 6:28 PM EDT
COSCIENS Biopharma Revenue
COSCIENS Biopharma had revenue of $2.34M in the quarter ending June 30, 2024, with 4.05% growth. This brings the company's revenue in the last twelve months to $4.92M, down -43.63% year-over-year. In the year 2023, COSCIENS Biopharma had annual revenue of $4.50M, down -20.25%.
Revenue (ttm)
$4.92M
Revenue Growth
-43.63%
P/S Ratio
n/a
Revenue / Employee
$409,583
Employees
12
Market Cap
12.47M
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.50M | -1.14M | -20.25% |
Dec 31, 2022 | 5.64M | 380.00K | 7.22% |
Dec 31, 2021 | 5.26M | 1.61M | 44.03% |
Dec 31, 2020 | 3.65M | 3.12M | 586.47% |
Dec 31, 2019 | 532.00K | -26.35M | -98.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareMax | 784.55M |
Star Equity Holdings | 47.15M |
Psychemedics | 20.79M |
TRxADE HEALTH | 7.45M |
QT Imaging Holdings | 3.11M |
Oncternal Therapeutics | 1.85M |
Senti Biosciences | 338.00K |
CSCI News
- 4 days ago - COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - GlobeNewsWire
- 18 days ago - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 24 days ago - Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. - GlobeNewsWire
- 6 weeks ago - Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders - GlobeNewsWire
- 2 months ago - Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - GlobeNewsWire
- 3 months ago - Aeterna Zentaris and Ceapro Complete Merger Transaction - GlobeNewsWire
- 3 months ago - Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date - GlobeNewsWire
- 3 months ago - Aeterna Zentaris Announces Details Regarding Transaction with Ceapro - GlobeNewsWire